Portal de investigación
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Datos básicos
- Código:
- UEB-2020-585
- Dotación:
- Año incial:
- 2020
- Año final:
- 2023
Objetivos del proyecto
1. To consolidate a Latin American network for clinical training and support of pharmacists and healthcare administrators (hospital financial decision makers) and involve them in the ASPs using the existing network (LASCONET) 2. To create a role model of ASPs with the active participation of pharmacists and healthcare administrators (hospital financial decision makers) by a. Providing training in clinical concepts and cost-effectiveness concepts applied to AMS, as well as defining which outcomes should be measured during the year of follow of the LASCONET hospitals involved. b. With an advisor and expert in healthcare economics Carlos Felipe Muñoz, MD, the hospital financial administrator and the pharmacists will have the opportunity to implement strategies to purchase antimicrobials c. With the advisory of Debra A. Goff, PharmD the hospital pharmacists will be trained in consumption and clinical outcomes of antimicrobials. 3. To consolidate the training of pharmacists and hospital financial decision makers in each of the participating countries under the guidance of the Universidad El Bosque group (RAEH) and the already LASCONET created network of hospitals.
Documentos
- No hay documentos
Participantes
Unidades de investigación
Outputs del proyecto
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections
Kanj SS; (...); van Duin D
Review. 10.1016/j.ijantimicag.2022.106633. 2022
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
Wang M.; (...); Zhang F.
Article. 10.1016/S1473-3099(21)00399-6. 2022
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
García-Betancur JC; (...); Villegas MV
Article. 10.3390/antibiotics11081101. 2022
Consenso de expertos para el tratamiento antimicrobiano de las infecciones causadas por bacilos gram negativos multirresistentes en pacientes adultos
Álvarez-Moreno C.A.; (...); Rojas S.Y.S.
Article. 10.22354/24223794.1130. 2023
Consensus recommendations based on evidence for abdominal sepsis in the pediatric and adult population of colombia
Oñate J.; (...); Villegas M.
Article. 10.22354/in.v25i4.954. 2021
Dynamics of blaKPC-2 Dissemination from Non-CG258 Klebsiella pneumoniae to Other Enterobacterales via IncN Plasmids in an Area of High Endemicity
Rada AM; (...); Restrepo E
Article. 10.1128/AAC.01743-20. 2020
Early appropriate diagnostics and treatment of MDR Gram-negative infections
Bassetti M; (...); Yu Y
Review. 10.1093/jacamr/dlac089. 2022
Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization
Gill C.M.; (...); Thomson K.
Article. 10.1128/AAC.01204-21. 2021
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: Results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India
Lazure P.; (...); Peloquin S.
Article. 10.1093/jacamr/dlac094. 2022
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India (vol 4, pg dlac094, 2022)
Lazure, P; (...); Peloquin, S
Correction. 10.1093/jacamr/dlad010. 2022
Genetic Diversity of Multidrug-Resistant Pseudomonas aeruginosa Isolates Carrying blaVIM–2 and blaKPC–2 Genes That Spread on Different Genetic Environment in Colombia
Rada AM; (...); Capataz C
Article. 10.3389/fmicb.2021.663020. 2021
Genomic analysis of ctx-m-group-1-producing extraintestinal pathogenic e. Coli (expec) from patients with urinary tract infections (uti) from colombia
Cadena E.D.L.; (...); Villegas MV
Article. 10.3390/antibiotics9120899. 2020
Global resilience and new strategies needed for antimicrobial stewardship during the COVID-19 pandemic and beyond
Goff D.A.; (...); Sanchez P.J.
Article. 10.1002/jac5.1622. 2022
Identification of mcr-1 Genes and Characterization of Resistance Mechanisms to Colistin in Escherichia coli Isolates from Colombian Hospitals
De La Cadena E; (...); Villegas MV
Article. 10.3390/antibiotics12030488. 2023
Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions
Pallares C; (...); Villegas MV
Article. 10.1186/s12879-022-07410-6. 2022
Microbiological and Clinical Aspects of Raoultella spp.
Appel TM; (...); Villegas MV
Review. 10.3389/fpubh.2021.686789. 2021
Molecular Analysis of Polymyxin Resistance among Carbapenemase-Producing Klebsiella pneumoniae in Colombia
de la Cadena, E; (...); Villegas, MV
Article. 10.3390/antibiotics10030284. 2021
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
Mojica M.F.; (...); Villegas M.V.
Article. 10.3389/fmicb.2022.1035609. 2022
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
Mojica MF; (...); Villegas MV
Article. 10.1128/msphere.00651-22. 2023
Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Pseudomonas aeruginosa Using the ERACE-PA Global Surveillance Program
Gill CM; (...); Nicolau DP
Article. 10.1093/ofid/ofab617. 2022
Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review
Moore LSP; (...); Apisarnthanarak A
Note. 10.1007/s40121-023-00815-z. 2023
Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate
Villegas, MV, Esparza, G, Reyes, J
Article. 10.1093/jacamr/dlab035. 2021
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
Gill C.M.; (...); Nicolau D.P.
Article. 10.1007/s10096-021-04308-0. 2021
The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients
Maraolo, AE; (...); Giacobbe, DR
Article. 10.1007/s40121-021-00408-8. 2021
Update on the epidemiology of carbapenemases in Latin America and the Caribbean
García-Betancur, JC; (...); Villegas, MV
Review. 10.1080/14787210.2020.1813023. 2021
Campos de estudio
Citar el proyecto
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs. (UEB-2020-585). 2020-2023. IP:MARIA VIRGINIA VILLEGAS BOTERO.